Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormono-refractory prostatic neoplasia and moderate-severe bone pain associated [Studio clinico randomizzato e controllato per comparare l'™efficacia analgesica dell'™associazione acido zoledronico e 153Sm-lexidronam verso acido zoledronico in pazienti affetti da metastasi ossee da neoplasia prostatica ormono-refrattaria con dolore associato a cancro di intensita' moderata-severa]

Trial Profile

Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormono-refractory prostatic neoplasia and moderate-severe bone pain associated [Studio clinico randomizzato e controllato per comparare l'™efficacia analgesica dell'™associazione acido zoledronico e 153Sm-lexidronam verso acido zoledronico in pazienti affetti da metastasi ossee da neoplasia prostatica ormono-refrattaria con dolore associato a cancro di intensita' moderata-severa]

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samarium 153 lexidronam (Primary) ; Zoledronic acid
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top